SCHEMBL4585969

SCHEMBL4585969

CC(C)n1cc(-c2nc(C(=O)O)c(N)nc2-c2ccc(F)cc2F)ccc1=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 8/20 0.51
ADORA1 P30542 5/20 0.51
PTGDR2 Q9Y5Y4 2/20 0.43
BMPR1B O00238 3/20 0.40
BMPR1A P36894 3/20 0.40
TGFBR1 P36897 3/20 0.40
ACVRL1 P37023 3/20 0.40
ACVR1 Q04771 3/20 0.40
DGAT1 O75907 2/20 0.36
SOAT1 P35610 2/20 0.36
MAPK14 Q16539 3/20 0.36
ADORA2B P29275 2/20 0.36
ADORA3 P0DMS8 1/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
KCNH2 Q12809 1/20 0.36
MAPK11 Q15759 1/20 0.36
LDHA P00338 1/20 0.36
ATR Q13535 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4584946 0.92 ADORA2A (0.51) ADORA2AADORA1PTGDR2BMPR1BBMPR1A
SCHEMBL4585041 0.92 ADORA2A (0.51) ADORA2AADORA1PTGDR2BMPR1BBMPR1A
SCHEMBL4584503 0.88 ADORA2A (0.64) ADORA2AADORA1PTGDR2BMPR1BBMPR1A
SCHEMBL4586413 0.88 ADORA2A (0.47) ADORA2AADORA1PTGDR2BMPR1BBMPR1A
SCHEMBL4584621 0.87 ADORA2A (0.54) ADORA2AADORA1PTGDR2BMPR1BBMPR1A
SCHEMBL4584638 0.87 ADORA2A (0.51) ADORA2AADORA1PTGDR2BMPR1BBMPR1A
SCHEMBL4584157 0.86 ADORA2A (0.50) ADORA2AADORA1PTGDR2BMPR1BBMPR1A
SCHEMBL4585016 0.84 ADORA2A (0.51) ADORA2AADORA1PTGDR2BMPR1BBMPR1A
SCHEMBL4586425 0.84 ADORA2A (0.46) ADORA2AADORA1BMPR1BBMPR1ATGFBR1
SCHEMBL4584817 0.82 ADORA2A (0.51) ADORA2AADORA1PTGDR2BMPR1BBMPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407961-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2008-08-05 US disclosed
EP-1678160-A1 PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF Astellas Pharma Inc. (JP) 2006-07-12 EP disclosed
US-20050113387-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-05-26 US disclosed
WO-2005040151-A1 PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF ASTELLAS PHARMA INC. (JP) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113387-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, P2RX5, ADORA1 ADORA2A 1/4885ADORA1 3/4885PTGDR2 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.